UAlbany Scientists Pioneer Innovative Laser Method to Evaluate mRNA Therapeutics

Messenger RNA (mRNA) technology has heralded a new era in biomedical science, revolutionizing our ability to instruct cells to produce critical proteins that empower the immune system to combat a vast array of diseases, from aggressive cancers to rare genetic disorders. The therapeutic potential of mRNA is underpinned by its capacity to provide transient, precise protein synthesis instructions, yet the molecule’s inherent instability poses substantial challenges to clinical application. To address this, mRNA molecules are encapsulated within lipid nanoparticles (LNPs), tiny fatty vesicles that shield the delicate RNA from enzymatic degradation and facilitate its delivery into target cells. However, ensuring the integrity of this encapsulation is vital; improperly packaged mRNA risks therapeutic failure or adverse effects.

In groundbreaking research from the University at Albany, a sophisticated technique leveraging Raman spectroscopy has been developed to ascertain whether mRNA is fully and correctly enclosed within lipid nanoparticles. Unlike conventional methods that necessitate the disruptive breakdown of nanoparticle structures, this approach offers a non-destructive, rapid assessment of mRNA encapsulation directly in the intact formulation. Raman spectroscopy, a laser-based analytical tool, probes molecular vibrations by measuring scattered light, yielding a chemical fingerprint unique to each material. By illuminating the sample with a laser and analyzing the spectrum of scattered photons, scientists can decode the molecular composition and interactions without physically altering the sample.

This innovative methodology hinges on the use of deep ultraviolet (UV) resonance Raman spectroscopy, a specialized variant designed to enhance the signal from nucleic acids in the presence of lipids. Since mRNA constitutes only a minor fraction within the lipid-rich environment of nanoparticles, its spectral signature is easily masked by the surrounding lipids when using traditional Raman spectroscopy. Deep UV excitation, however, exploits the intrinsic absorbance properties of nucleic acids, amplifying their Raman response while suppressing interference from lipids. This allows for selective observation of mRNA molecules nestled inside the nanoparticles, thus providing an unparalleled window into the quality of encapsulation.

Led by Professor Igor Lednev, the research team crafted a bespoke deep-UV Raman instrument capable of precisely targeting mRNA molecules in complex vaccine samples. The instrument generates laser light at ultraviolet wavelengths, harnessing resonance effects to magnify the otherwise weak spectral signals from RNA. Coupled with advanced statistical models and machine learning algorithms, the system quantitatively evaluates whether each mRNA strand is fully sequestered within lipid vesicles or partially exposed, which could undermine therapeutic efficacy. This analytical innovation not only preserves the sample intact for further testing but also promises to dramatically accelerate quality control processes in vaccine and therapeutic development.

The implications of this technology are profound, particularly as mRNA vaccines become a mainstay in global healthcare. Current analytical techniques to verify lipid nanoparticle integrity often involve destructive sample preparation, including chemical disruption or extraction procedures that obliterate the native structure. These methods are laborious and incapable of providing rapid feedback during manufacturing or research. By contrast, Raman spectroscopy offers instantaneous chemical characterization, maintaining the original state of the vaccine formulation. Such real-time monitoring capabilities could enable pharmaceutical manufacturers to optimize lipid formulations iteratively, balancing the requirements of stability, delivery efficiency, and safety.

Professor Alexander Shekhtman, a collaborator on the project and an expert in RNA biochemistry at the University at Albany’s RNA Institute, underscores the method’s ability to surmount longstanding hurdles in nanoparticle analysis. “The fragility of intact lipid nanoparticles and their heterogeneity have historically complicated characterization efforts,” Shekhtman explains. “Our application of Raman spectroscopy allows the analysis of mRNA within these particles without compromising their structure, facilitating the design of next-generation therapeutics with improved profiles.” This approach may herald a paradigm shift in how researchers and manufacturers evaluate mRNA delivery systems.

Beyond its immediate application to mRNA encapsulation, the technology reflects a broader trend toward integrating advanced photonic tools with computational analytics in biomedicine. Raman spectroscopy itself has endured as a versatile method in chemistry and materials science, yet its fusion with powerful data-driven interpretation—such as machine learning—enhances resolution and specificity. Professor Lednev’s lab has been at the forefront of this convergence, previously pioneering Raman-based methods for forensic investigations and the early detection of neurodegenerative diseases via noninvasive molecular fingerprints. The current advancement embodies the lab’s commitment to translating optical spectroscopy innovations into impactful biomedical solutions.

This laser-driven analytical advance could soon become indispensable not only in late-stage quality control but also in the early research phases of mRNA therapeutic design. By providing immediate feedback on nanoparticle formulation efficacy, researchers can rapidly iterate on lipid compositions and mRNA loading strategies to optimize delivery mechanisms. The ability to non-destructively verify encapsulation ensures that formulations entering clinical trials have consistent, reproducible quality, ultimately driving safer and more effective treatments for patients worldwide.

The collaboration that fueled this breakthrough spans continents, engaging researchers from the University at Albany and Kangwon National University in South Korea. Sila Jin and Young Mee Jung contributed to the project, supported by a training grant from the National Research Foundation of Korea. Their partnership highlights the increasingly globalized nature of biomedical innovation, wherein expertise and technology coalesce across borders to solve pressing healthcare challenges.

This research exemplifies how advances in laser spectroscopy and photonics can be harnessed to meet the precise demands of modern medicine. By unveiling the molecular intricacies of mRNA encapsulation within lipid nanoparticles, the technique offers a powerful tool to ensure that these cutting-edge therapeutics reach patients with the highest standards of safety and effectiveness. As mRNA therapies continue to evolve, such analytical breakthroughs will be critical pillars supporting their widespread adoption and success against a myriad of diseases.

—

News Publication Date: February 26, 2026

Web References:
https://pubs.acs.org/doi/10.1021/acs.analchem.5c04246

References:
Igor Lednev et al., Analytical Chemistry, 15-Jan-2026, DOI: 10.1021/acs.analchem.5c04246

Keywords

Analytical chemistry, Spectroscopy, RNA, Messenger RNA, Lipid nanoparticles, mRNA therapeutics, Deep-UV Raman spectroscopy, Molecular diagnostics, Vaccine quality control